Finanzen von Accelerate Diagnostics Inc (AXDX)AXDXAccelerate Diagnostics Inc

Accelerate Diagnostics Inc (AXDX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Products, accounting for 88.1% of total sales, equivalent to $2.63M. Another important revenue stream is Services. Understanding this composition is critical for investors evaluating how AXDX navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Accelerate Diagnostics Inc maintains a gross margin of 15.94%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -281.68%, while the net margin is -340.52%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively AXDX converts its operational activities into shareholder value.

In the context of the broader market, AXDX competes directly with industry leaders such as HSCS and BIAF. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, AXDX's gross margin of 15.94% stands against HSCS's 59.06% and BIAF's 23.91%. Such benchmarking helps identify whether Accelerate Diagnostics Inc is trading at a premium or discount relative to its financial performance.